Paragon Biosciences company gets $250M • Lurie's $25M health center
Crain's Health Pulse is your source for actionable, exclusive and inside news on the health care industry.
Source: chicagobusiness.com
Chicago Based Emalex News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Chicago Based Emalex. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Chicago Based Emalex Today - Breaking & Trending Today
Bain Capital-Backed Emalex Bio Lands $250M for Pivotal Test of Tourette Drug
Emalex Biosciences will use the cash from its Series D financing to conduct a Phase 3 clinical trial for ecopipam, an experimental treatment for Tourette syndrome. Though there drugs are already available for Tourette, Emalex’s drug addresses a different central nervous system target that the biotech believes could offer an edge.
Source: medcitynews.com
Emalex raises $250 million for Tourette's drug development | Crain's Chicago Business
Emalex plans to use the money to launch the largest North American clinical trial for a Tourette Syndrome drug and to potentially bring the drug to market.
Source: chicagobusiness.com